In today's competitive market Life-Cycle Management of drugs begins before launch of the actual product. The commonplace approach using combinatorial chemistry frequently optimizes lead molecules which are poorly or completely insoluble in aqueous media often coupled with low permeability across membranes. These factors cause low total bioavailability and pose a significant challenge to formulators. Enhanced formulations or changes in solid-state are advocated for a successful extension of the life-cycle of a drug.

Activery offers options in both fields: Nanoparticles with a highly enlarged surface area or amorphous particles without a crystal lattice as alternatives to traditional crystalline solids, and co-precipitation of drugs or combinations of drugs with or without excipients as approach to aid subsequent formulations.